MDBH

MDB CapitalB

Nasdaq / Financial Services

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$4.10

+25.8% vs current

Most likely

Base case

50%

Probability

Target price

$3.15

-3.4% vs current

B-

Bear case

25%

Probability

Target price

$2.00

-38.7% vs current

AI sentiment snapshot

Latest data as of 2026-06-21

AI commentary

This remains a low-coverage monitoring memo, not a conviction upgrade. The evidence improved because a primary company release on March 31, 2026 supplied usable operating and asset context, and a June 3, 2026 company presentation notice showed management still marketing the story publicly [#PR-2026-03-31][#PR-2026-06-03]. Even so, trusted recent third-party coverage is sparse, analyst revision data is unavailable, social context is absent, and the deterministic prior only points to modest positive returns with moderate thesis-change intensity. Using the latest anchor close of $2.95 on 2026-06-18, the stock looks like a cautious hold tied to future monetization proof rather than a clean near-term rerating.

RankAlpha Sentiment Codex - 2026-06-21

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-14catalystNext filing tests burn rate against disclosed asset baseHigh impact

Management said 2025 fixed operating expenses were about $10 million, net cash used was about $5.7 million, and year-end cash/current assets/marketable securities less liabilities were about $22.3 million, so the next quarterly filing is the clearest near-term check on whether liquidity remains supportive of the platform without new dilution [#PR-2026-03-31][#SEC-10Q-2026-05-14].

2026-10-31eventMDB Direct partnership or distribution expansion could validate monetizationHigh impact

The company said MDB Direct is in active discussions for a strategic partnership intended to realize value from the self-clearing asset and expand distribution reach, making a concrete partnership or launch update the most important discrete upside event from here [#PR-2026-03-31].

2026-12-31catalystPatentVest and portfolio-company monetization remain option value, not yet proven earnings powerHigh impact

Management highlighted PatentVest's planned spin-out path, Paulex Bio's expected clinical-trial initiation later in 2026 with an IPO target for September 2026, and continued visibility for portfolio assets, but the thesis stays cautious until those assets convert into funded transactions or durable fee economics [#PR-2026-03-31][#PR-EARNINGS-2026-04-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-21 • Updated nightlySource: Internal modelMethodology